Is Egrifta (Tesamorelin) Legal in California?

HealthRX.com

Egrifta is FDA approved, with one labeled use

1.4 mgEgrifta SV labeled dose, given once daily under the SV labelSource: dailymed.nlm.nih.gov

Print or save as PDF

Key numbers

  • 1.28 mgEgrifta WR labeled dose, given once daily under the WR labelSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 2 mgVial strength of the Egrifta SV product, one of the two current labeled productsSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 1.4 mgEgrifta SV labeled dose, given once daily under the SV labelSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026

See the public record for Tesamorelin

  • FDA status / Approved prescription drug, BLA 022505, first approved November 10, 2010 [1]
  • Approved use / Excess abdominal fat in HIV-infected adults with lipodystrophy [2]
  • Current products / Egrifta SV 1.4 mg and Egrifta WR 1.28 mg, once daily subcutaneous, not substitutable [2][3]
  • Boxed warning / None in the current SV or WR label [2][3]
  • Compounding / No category-based FDA statement; not on the significant-safety-risk list [4][5][6]
  • Sport / WADA prohibits it at all times under S2.2.4 [7]

What the federal approval record shows

Egrifta is tesamorelin acetate, approved on November 10, 2010 as application 022505, a new molecular entity [1]. The original new drug application was deemed a biologic license application on March 23, 2020 [1]. Two labeled products are current: Egrifta SV, a 2 mg vial, and Egrifta WR, an 11.6 mg vial, both once-daily subcutaneous injections with labels dated July 29, 2026 [2][3]. Neither label carries a boxed warning [2][3].

The approved indication is narrow. Egrifta is indicated only for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy [2]. The label states that it is not indicated for weight loss management because it has a weight-neutral effect, that long-term cardiovascular safety has not been established, and that there are no data showing improved adherence to antiretroviral therapy [2]. Use in people without HIV lipodystrophy sits outside that labeled indication.

The two labeled products are not interchangeable. The Egrifta SV label gives a dose of 1.4 mg, which is 0.35 mL of the reconstituted 2 mg per 0.5 mL solution, injected subcutaneously into the abdomen once daily [2]. The Egrifta WR label gives a dose of 1.28 mg, or 0.16 mL of the reconstituted 8 mg/mL solution, once daily [3]. The labels state that Egrifta WR and Egrifta SV are not substitutable [3].

Is compounded tesamorelin legal?

FDA keeps a page of bulk drug substances that may present significant safety risks when compounded, a list for state-licensed pharmacies and physicians, and a list for outsourcing facilities. Tesamorelin appears on none of them. It is absent from the significant-safety-risk page (content dated 04/22/2026) [4], from every category of the state-licensed pharmacy and physician list (updated May 14, 2026) [5], and from every category of the outsourcing facility list (updated March 21, 2025) [6]. FDA has made no category-based statement about compounding tesamorelin.

Tesamorelin is already a component of an FDA-approved drug, Egrifta [2]. Compounded drugs are not FDA-approved: FDA does not review their safety, effectiveness or quality before they are marketed [8].

A separate HHS draft policy, filed on October 28, 2026 (Federal Register document 2026-22192, publication scheduled October 30, 2026), sets out enforcement discretion for six peptides: BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500. Tesamorelin is not one of the six [9][8].

Questions worth asking

Choose the questions you want to keep

Does WADA prohibit tesamorelin?

Yes. WADA's Prohibited List names tesamorelin in S2.2.4, in the growth hormone releasing factors class (GHRH and its analogues, listed alongside CJC-1293, CJC-1295 and sermorelin) [7]. It is prohibited at all times, in and out of competition, and S2 substances are non-Specified Substances [7]. It is on the 2026 List, in force since January 1, 2026, and remains on the 2027 List [7][10].

Check what you know

Think you have it? Try 4 quick questions and see what the article says.

1. What dose does the Egrifta SV label give?

Question 1 of 4

Score: 0 right, 0 of 4 answered

What is Egrifta's federal legal status?
Egrifta (tesamorelin acetate) is an FDA-approved prescription drug, application BLA 022505, first approved November 10, 2010, for reducing excess abdominal fat in HIV-infected adults with lipodystrophy [1][2].
Is Egrifta legal in California?
Egrifta is an FDA-approved prescription drug with one labeled use [1][2]. California-specific prescribing, telehealth and pharmacy requirements, if any, are not established here.
Is compounded tesamorelin legal?
FDA has made no category-based statement about compounding tesamorelin. It is not on the agency's significant-safety-risk bulk substance page, and it appears in no category of the lists for state-licensed pharmacies and physicians or for outsourcing facilities [4][5][6]. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they are marketed [8].
Is Egrifta approved for weight loss?
No. The label says it is not indicated for weight loss management because it has a weight-neutral effect. The only approved use is reduction of excess abdominal fat in HIV-infected adults with lipodystrophy [2].
Does WADA ban tesamorelin?
Yes. WADA's Prohibited List names tesamorelin in S2.2.4 among growth hormone releasing factors, prohibited at all times in and out of competition, and it remains on the 2027 List [7][10].
What dose do the current labels give?
The Egrifta SV label gives 1.4 mg injected subcutaneously into the abdomen once daily; the Egrifta WR label gives 1.28 mg once daily [2][3]. The labels state that the two are not substitutable [3].

Reader questions

What people actually ask

Short answers drawn from the sources this article cites.

Is Egrifta the same as tesamorelin?

Yes. Egrifta is the brand name for tesamorelin acetate, a new molecular entity approved by the FDA on November 10, 2010 under application 022505. Its one labeled use is reducing excess abdominal fat in HIV-infected adults with lipodystrophy.

Is tesamorelin FDA certified?

Egrifta, the brand of tesamorelin acetate, is FDA-approved. It was first approved November 10, 2010 under application BLA 022505, and the original new drug application was deemed a biologic license application on March 23, 2020.

Who is not allowed to take tesamorelin?

The labeled use is narrow: Egrifta is indicated only for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. Use in people without HIV lipodystrophy sits outside that labeled indication. Athletes are also barred, since WADA prohibits tesamorelin at all times.

Show all 10 referencesHide references
  1. Drugs@FDA: FDA-Approved Drugs.
  2. U.S. National Library of Medicine, DailyMed. Egrifta SV (tesamorelin) for injection, 2 mg vial prescribing information. Egrifta SV (tesamorelin) for injection, 2 mg vial label
  3. U.S. National Library of Medicine, DailyMed. Egrifta WR (tesamorelin) for injection, 11.6 mg vial prescribing information. Egrifta WR (tesamorelin) for injection, 11.6 mg vial label
  4. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
  5. U.S. Food and Drug Administration.
  6. U.S. Food and Drug Administration.
  7. World Anti-Doping Agency.
  8. Official web page.
  9. Official web page.
  10. World Anti-Doping Agency.
Evidence overview for Is Egrifta (Tesamorelin) Legal in California?